{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:16:39Z","timestamp":1744344999530},"reference-count":72,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1053\/j.ackd.2005.07.008","type":"journal-article","created":{"date-parts":[[2005,9,29]],"date-time":"2005-09-29T13:42:55Z","timestamp":1128001375000},"page":"385-396","source":"Crossref","is-referenced-by-count":15,"title":["Anemia in Children with Chronic Kidney Disease"],"prefix":"10.1053","volume":"12","author":[{"given":"Larry A.","family":"Greenbaum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2005.07.008_bib1","first-page":"449","article-title":"Erythropoietin and inhibitors of in vitro erythropoiesis in the development of anemia in children with renal disease","volume":"105","author":"McGonigle","year":"1985","journal-title":"J Lab Clin Med"},{"key":"10.1053\/j.ackd.2005.07.008_bib2","first-page":"481","article-title":"Hemolysis and blood loss in children with chronic renal failure","volume":"8","author":"Muller-Wiefel","year":"1977","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib3","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1016\/S0272-6386(01)70008-X","article-title":"NKF-K\/DOQI Clinical practice guidelines for anemia of chronic kidney disease","volume":"37","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib4","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S0272-6386(03)00110-0","article-title":"Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder National Kidney Foundation Carnitine Consensus Conference","volume":"41","author":"Eknoyan","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib5","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1681\/ASN.V781178","article-title":"Is erythropoietin a survival factor for red blood cells?","volume":"7","author":"Polenakovic","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0272-6386(03)00788-1","article-title":"A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response","volume":"42","author":"Richardson","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib7","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1046\/j.1523-1755.2003.00184.x","article-title":"Anemia in pediatric hemodialysis patients","volume":"64","author":"Frankenfield","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2005.07.008_bib8","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ajkd.2003.07.016","article-title":"Malnutrition-inflammation complex syndrome in dialysis patients","volume":"42","author":"Kalantar-Zadeh","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0272-6386(97)90339-5","article-title":"High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients","volume":"29","author":"Barany","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/ndt\/16.2.224","article-title":"Inflammation, serum C-reactive protein, and erythropoietin resistance","volume":"16","author":"Barany","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2005.07.008_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1056\/NEJM199301213280304","article-title":"Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia","volume":"328","author":"Rao","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2005.07.008_bib12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000188758","article-title":"Folic acid supplementation improves erythropoietin response","volume":"71","author":"Pronai","year":"1995","journal-title":"Nephron"},{"key":"10.1053\/j.ackd.2005.07.008_bib13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0272-6386(85)80092-5","article-title":"Aluminum-induced anemia","volume":"6","author":"Kaiser","year":"1985","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000187080","article-title":"Effect of low doses of L-carnitine on the response to recombinant human erythropoietin in hemodialyzed children","volume":"62","author":"Berard","year":"1992","journal-title":"Nephron"},{"key":"10.1053\/j.ackd.2005.07.008_bib15","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/ndt\/14.8.1912","article-title":"The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients","volume":"14","author":"Erturk","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2005.07.008_bib16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1523-1755.2004.00357.x","article-title":"Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients","volume":"65","author":"Chavers","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2005.07.008_bib17","first-page":"S1","article-title":"Centers for Medicare & Medicaid Services","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00467-004-1544-7","article-title":"Anemia in pediatric dialysis patients in end-stage renal disease network 5","volume":"19","author":"Fadrowski","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib19","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1046\/j.1523-1755.2000.00289.x","article-title":"Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy","volume":"58","author":"Foley","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2005.07.008_bib20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.263.6.825","article-title":"The quality of life of hemodialysis recipients treated with recombinant human erythropoietin","volume":"263","author":"Evans","year":"1990","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2005.07.008_bib21","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0272-6386(95)90122-1","article-title":"Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients","volume":"25","author":"Revicki","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/bmj.300.6724.573","article-title":"Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis","volume":"300","year":"1990","journal-title":"BMJ"},{"key":"10.1053\/j.ackd.2005.07.008_bib23","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1523-1755.2004.00810.x","article-title":"Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients","volume":"66","author":"Frank","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2005.07.008_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ndt\/gfg458","article-title":"Anaemia in haemodialysis patients of five European countries","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2005.07.008_bib25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1523-1755.2004.00797.x","article-title":"Treating anemia early in renal failure patients slows the decline of renal function","volume":"66","author":"Gouva","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2005.07.008_bib26","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.ajkd.2004.08.024","article-title":"Anemia and health-related quality of life in adolescents with chronic kidney disease","volume":"44","author":"Gerson","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0022-3476(05)80688-2","article-title":"Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis","volume":"117","author":"Montini","year":"1990","journal-title":"J Pediatr"},{"key":"10.1053\/j.ackd.2005.07.008_bib28","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF00860930","article-title":"Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure","volume":"9","author":"Burke","year":"1995","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib29","first-page":"546","article-title":"Primary results from the U.S. multicenter pediatric recombinant erythropoietin (EPO) study","volume":"5","author":"Jabs","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib30","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/BF00866771","article-title":"The effects of recombinant human erythropoietin on growth and nutritional status","volume":"10","author":"Jabs","year":"1996","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib31","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00467-003-1214-1","article-title":"Morbidity and mortality in children with anemia at initiation of dialysis","volume":"18","author":"Warady","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib32","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1523-1755.2002.00472.x","article-title":"Cardiovascular disease in pediatric chronic dialysis patients","volume":"62","author":"Chavers","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2005.07.008_bib33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/adc.71.2.119","article-title":"Cardiovascular abnormalities in end stage renal failure","volume":"71","author":"Morris","year":"1994","journal-title":"Arch Dis Child"},{"key":"10.1053\/j.ackd.2005.07.008_bib34","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0272-6386(97)90116-5","article-title":"A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease","volume":"29","author":"Hutchinson","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib35","first-page":"393","article-title":"Iron induced increase in red cell size in haemodialysis patients","volume":"48","author":"Gokal","year":"1979","journal-title":"Q J Med"},{"key":"10.1053\/j.ackd.2005.07.008_bib36","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s004670050352","article-title":"Recombinant human erythropoietin dosage in children undergoing hemodialysis and continuous ambulatory peritoneal dialysis","volume":"11","author":"Sieniawska","year":"1997","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib37","unstructured":"Ho M, Stablein DM: North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) Annual Report. Rockville, MD, 2003"},{"key":"10.1053\/j.ackd.2005.07.008_bib38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s004670050583","article-title":"Safety and efficacy of erythropoietin in children with chronic renal failure","volume":"13","author":"Brandt","year":"1999","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib39","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s004670050294","article-title":"Low-dose erythropoietin is effective and safe in children on continuous ambulatory peritoneal dialysis","volume":"11","author":"Yalcinkaya","year":"1997","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"346","author":"Casadevall","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2005.07.008_bib41","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1097\/01.ASN.0000135056.81056.A4","article-title":"Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis","volume":"15","author":"Asari","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/ajkd.2002.33919","article-title":"Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients","volume":"40","author":"Nissenson","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib43","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1046\/j.1523-1755.2002.00657.x","article-title":"Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients","volume":"62","author":"Vanrenterghem","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2005.07.008_bib44","series-title":"National Kidney Foundation Clinical Nephrology Meeting","article-title":"Aranesp (darbepoetin alfa) administered at a reduced frequency of once every 4 weeks (Q4W) maintains hemoglobin levels in patients with chronic kidney disease (CKD) receiving dialysis","author":"Walker","year":"2002"},{"key":"10.1053\/j.ackd.2005.07.008_bib45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00467-003-1364-1","article-title":"Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis","volume":"19","author":"De Palo","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib46","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00467-002-0932-0","article-title":"Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease","volume":"17","author":"Lerner","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib47","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.V10112392","article-title":"Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients","volume":"10","author":"Macdougall","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/ndt\/6.10.709","article-title":"Pharmacokinetics of recombinant human erythropoietin in children with renal failure","volume":"6","author":"Evans","year":"1991","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2005.07.008_bib49","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1592\/phco.22.14.160S.33398","article-title":"Dose conversion from recombinant human erythropoietin to darbepoetin alfa","volume":"22","author":"Scott","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.ackd.2005.07.008_bib50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0272-6386(99)70103-4","article-title":"A study of parenteral iron regimens in hemodialysis patients","volume":"34","author":"Besarab","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib51","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s004670050747","article-title":"Intravenous iron treatment of renal anemia in children on hemodialysis","volume":"13","author":"Tenbrock","year":"1999","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib52","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/s004670000326","article-title":"Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients","volume":"14","author":"Greenbaum","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib53","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/000992289203100206","article-title":"Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO)","volume":"31","author":"Campos","year":"1992","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1053\/j.ackd.2005.07.008_bib54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF00868261","article-title":"Assessing iron status in children with chronic renal failure on erythropoietin","volume":"8","author":"Morris","year":"1994","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib55","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1681\/ASN.V7122654","article-title":"The evaluation of iron status in hemodialysis patients","volume":"7","author":"Fishbane","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib56","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00467-003-1126-0","article-title":"The management of anemia in pediatric peritoneal dialysis patients","volume":"18","author":"Schroder","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib57","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s00467-004-1421-4","article-title":"Intravenous iron therapy in pediatric hemodialysis patients","volume":"19","author":"Gillespie","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib58","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s004670000453","article-title":"Sodium ferric gluconate therapy in renal transplant and renal failure patients","volume":"15","author":"Yorgin","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib59","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s004670100645","article-title":"Maintenance intravenous iron therapy in pediatric hemodialysis patients","volume":"16","author":"Morgan","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib60","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s00467-005-1904-y","article-title":"Sodium ferric gluconate complex therapy in anemic children on hemodialysis","volume":"20","author":"Warady","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib61","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00467-004-1457-5","article-title":"Iron therapy in the pediatric hemodialysis population","volume":"19","author":"Warady","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib62","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0272-6386(99)70184-8","article-title":"Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients","volume":"33","author":"Nissenson","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib63","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00467-003-1288-9","article-title":"Intermittent versus maintenance iron therapy in children on hemodialysis","volume":"19","author":"Ruiz-Jaramillo Mde","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib64","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/ajkd.2003.50141","article-title":"Chronic use of sodium ferric gluconate complex in hemodialysis patients","volume":"41","author":"Folkert","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib65","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/ajkd.2001.28587","article-title":"Intravenous iron sucrose","volume":"38","author":"Chandler","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib66","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0272-6386(01)80123-2","article-title":"Suspected iron dextran-related adverse drug events in hemodialysis patients","volume":"37","author":"Fletes","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2005.07.008_bib67","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1523-1755.2003.00703.x","article-title":"Sodium ferric gluconate complex in hemodialysis patients","volume":"63","author":"Coyne","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2005.07.008_bib68","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0022-2143(98)90098-1","article-title":"Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran","volume":"131","author":"Auerbach","year":"1998","journal-title":"J Lab Clin Med"},{"key":"10.1053\/j.ackd.2005.07.008_bib69","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/oxfordjournals.ndt.a092122","article-title":"Serious adverse reactions after intravenous ferric gluconate","volume":"7","author":"Pascual","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2005.07.008_bib70","first-page":"528","article-title":"Parenteral iron therapy","volume":"128","author":"Hoigne","year":"1998","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1053\/j.ackd.2005.07.008_bib71","doi-asserted-by":"crossref","first-page":"457","DOI":"10.5414\/CNP57457","article-title":"Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients","volume":"57","author":"Hoen","year":"2002","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2005.07.008_bib72","first-page":"S1","article-title":"European best practice guidelines for the management of anaemia in patients with chronic renal failure","volume":"14","year":"1999","journal-title":"Nephrol Dial Transplant"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559505001217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559505001217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T04:43:19Z","timestamp":1626583399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559505001217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S1548559505001217"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2005.07.008","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}